Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 6NIH 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

Cyclophosphamide 385Specimen Handling 370Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Interventional × Naproxen × Clear all
NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
59 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

NCT02052908 2021-01-25

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
81 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡